 | • レポートコード：MRC2303L059 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、234ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料によると、フェニルケトン尿症治療の世界市場規模は2021年に580.28百万ドル、2022年に655.97百万ドルとなり、その後CAGR 13.21％で成長して2027年までに1,222.30百万ドルに到達する見通しです。本書では、世界のフェニルケトン尿症治療市場について多面的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、投与経路別分析（経口薬、非経口薬）、製品別分析（栄養補助食品、医薬品）、流通別分析（ドラッグストア、病院薬局、オンライン薬局、小児科クリニック）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目をまとめています。なお、本書には、Ajinomoto Cambrooke, Inc.、American Gene Technologies International Inc.、BioMarin Pharmaceutical Inc.、Codexis, Inc.、Daiichi Sankyo Company, Limited、Danone S.A.、Endo International PLC、ERYTECH Pharma S.A.、Reckitt Benckiser Group PLCなどの企業情報を掲載しています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のフェニルケトン尿症治療市場規模：投与経路別 - 経口薬の市場規模 - 非経口薬の市場規模 ・世界のフェニルケトン尿症治療市場規模：製品別 - 栄養補助食品の市場規模 - 医薬品の市場規模 ・世界のフェニルケトン尿症治療市場規模：流通別 - ドラッグストアチャネルの市場規模 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小児科クリニックチャネルの市場規模 ・世界のフェニルケトン尿症治療市場規模：地域別 - 南北アメリカのフェニルケトン尿症治療市場規模 アメリカのフェニルケトン尿症治療市場規模 カナダのフェニルケトン尿症治療市場規模 ブラジルのフェニルケトン尿症治療市場規模 ... - アジア太平洋のフェニルケトン尿症治療市場規模 日本のフェニルケトン尿症治療市場規模 中国のフェニルケトン尿症治療市場規模 インドのフェニルケトン尿症治療市場規模 韓国のフェニルケトン尿症治療市場規模 台湾のフェニルケトン尿症治療市場規模 ... - ヨーロッパ/中東/アフリカのフェニルケトン尿症治療市場規模 イギリスのフェニルケトン尿症治療市場規模 ドイツのフェニルケトン尿症治療市場規模 フランスのフェニルケトン尿症治療市場規模 ロシアのフェニルケトン尿症治療市場規模 ... - その他地域のフェニルケトン尿症治療市場規模 ・競争状況 ・企業情報 |
The Global Phenylketonuria Treatment Market size was estimated at USD 580.28 million in 2021 and expected to reach USD 655.97 million in 2022, and is projected to grow at a CAGR 13.21% to reach USD 1,222.30 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Phenylketonuria Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Route of Administration, the market was studied across Oral and Parenteral.
Based on Product, the market was studied across Dietary Supplement and Drugs. The Drugs is further studied across Biopten and Kuvan.
Based on Distribution, the market was studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Pediatric Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Phenylketonuria Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Phenylketonuria Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Phenylketonuria Treatment Market, including Ajinomoto Cambrooke, Inc., American Gene Technologies International Inc., BioMarin Pharmaceutical Inc., Codexis, Inc., Daiichi Sankyo Company, Limited, Danone S.A., Endo International PLC, ERYTECH Pharma S.A., Reckitt Benckiser Group PLC, SOM Innovation Biotech, S.A., Synthetic Biologics, Inc., and Ultragenyx Pharmaceutical Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Phenylketonuria Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Phenylketonuria Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Phenylketonuria Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Phenylketonuria Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Phenylketonuria Treatment Market?
6. What is the market share of the leading vendors in the Global Phenylketonuria Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Phenylketonuria Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of phenylketonuria (PKU) disorders
5.1.1.2. Growing research in the field of genomics and biotechnology
5.1.1.3. Benefits associated with ongoing and after the phenylketonuria treatment
5.1.2. Restraints
5.1.2.1. Unfavorable reimbursement policies
5.1.3. Opportunities
5.1.3.1. Future potential due to stock of pipeline drugs
5.1.4. Challenges
5.1.4.1. Overall high cost associated with PKU treatment
5.2. Cumulative Impact of COVID-19
6. Phenylketonuria Treatment Market, by Route of Administration
6.1. Introduction
6.2. Oral
6.3. Parenteral
7. Phenylketonuria Treatment Market, by Product
7.1. Introduction
7.2. Dietary Supplement
7.3. Drugs
7.4.1. Biopten
7.4.2. Kuvan
8. Phenylketonuria Treatment Market, by Distribution
8.1. Introduction
8.2. Drug Stores
8.3. Hospital Pharmacies
8.4. Online Pharmacies
8.5. Pediatric Clinics
9. Americas Phenylketonuria Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Phenylketonuria Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Phenylketonuria Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Ajinomoto Cambrooke, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. American Gene Technologies International Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. BioMarin Pharmaceutical Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Codexis, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Daiichi Sankyo Company, Limited
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Danone S.A.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Endo International PLC
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. ERYTECH Pharma S.A.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Reckitt Benckiser Group PLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. SOM Innovation Biotech, S.A.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Synthetic Biologics, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Ultragenyx Pharmaceutical Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing